SM Tolaney

469 total citations
40 papers, 323 citations indexed

About

SM Tolaney is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, SM Tolaney has authored 40 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in SM Tolaney's work include Advanced Breast Cancer Therapies (24 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (16 papers). SM Tolaney is often cited by papers focused on Advanced Breast Cancer Therapies (24 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (16 papers). SM Tolaney collaborates with scholars based in United States, United Kingdom and Spain. SM Tolaney's co-authors include Vassiliki Karantza, Sami Diab, Gursel Aktan, D. Xing, Kevin Kalinsky, LA Carey, Virginia Kaklamani, Soamnauth Misir, Martin Olivo and EP Winer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

SM Tolaney

37 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
SM Tolaney United States	9	287	123	120	48	47	40	323
Marie-Pascale Graas Belgium	5	307 1.1×	183 1.5×	106 0.9×	103 2.1×	22 0.5×	8	389
P. Schmid United Kingdom	3	287 1.0×	142 1.2×	113 0.9×	49 1.0×	67 1.4×	4	343
Ning Liao China	10	184 0.6×	84 0.7×	128 1.1×	57 1.2×	17 0.4×	23	277
L Ryvo Israel	5	462 1.6×	173 1.4×	140 1.2×	95 2.0×	167 3.6×	8	544
A. Swat Switzerland	4	305 1.1×	135 1.1×	112 0.9×	45 0.9×	89 1.9×	6	354
Anna Barbro Sætersdal Norway	7	197 0.7×	61 0.5×	125 1.0×	96 2.0×	19 0.4×	7	284
Mahesh Shivhare United Kingdom	8	178 0.6×	80 0.7×	48 0.4×	45 0.9×	33 0.7×	14	256
Julie Tisserand France	7	191 0.7×	104 0.8×	84 0.7×	91 1.9×	75 1.6×	8	289
M. Nechaeva Russia	8	326 1.1×	164 1.3×	100 0.8×	57 1.2×	104 2.2×	17	401
Cecilie Bendigtsen Schirmer Norway	9	278 1.0×	87 0.7×	209 1.7×	59 1.2×	19 0.4×	14	318

Countries citing papers authored by SM Tolaney

Since Specialization

Citations

This map shows the geographic impact of SM Tolaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SM Tolaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SM Tolaney more than expected).

Fields of papers citing papers by SM Tolaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SM Tolaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SM Tolaney. The network helps show where SM Tolaney may publish in the future.

Co-authorship network of co-authors of SM Tolaney

This figure shows the co-authorship network connecting the top 25 collaborators of SM Tolaney. A scholar is included among the top collaborators of SM Tolaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SM Tolaney. SM Tolaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnston, S., et al.. (2025). 215P Real-world survival outcomes by risk features in patients with HR+, HER2− early breast cancer (EBC) in the US. ESMO Open. 10. 104769–104769.

Grinshpun, Albert, Shan Ren, Noah Graham, et al.. (2024). Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO Open. 9(6). 103465–103465. 4 indexed citations

Llombart‐Cussac, Antonio, et al.. (2024). 1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer. ESMO Open. 9. 103011–103011. 2 indexed citations

Graham, Noah, Melissa E. Hughes, Karen L. Smith, et al.. (2024). 213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC). ESMO Open. 9. 103235–103235. 3 indexed citations

Bardia, Aditya, Laura M. Spring, Dejan Juric, et al.. (2020). 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer. Annals of Oncology. 31. S394–S394. 5 indexed citations

Hurvitz, Sara A., Linda T. Vahdat, Nadia Harbeck, et al.. (2020). 353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer. Annals of Oncology. 31. S390–S390. 4 indexed citations

Kalinsky, Kevin, SJ Isakoff, SM Tolaney, et al.. (2019). Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC). Cancer Research. 79(4_Supplement). P2–11. 3 indexed citations

Goel, Shom, et al.. (2019). Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer. Cancer Research. 79(4_Supplement). P6–18. 1 indexed citations

Barroso‐Sousa, Romualdo, et al.. (2018). Abstract OT1-02-02: A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancer. Cancer Research. 78(4_Supplement). OT1–2. 1 indexed citations

10.

Bardia, Aditya, Linda T. Vahdat, Jennifer R. Diamond, et al.. (2018). Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results. Cancer Research. 78(4_Supplement). GS1–7. 12 indexed citations

11.

Tolaney, SM, Kevin Kalinsky, Virginia Kaklamani, et al.. (2018). Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Cancer Research. 78(4_Supplement). PD6–13. 56 indexed citations

12.

Tolaney, SM, et al.. (2017). Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Cancer Research. 77(4_Supplement). P5–15. 8 indexed citations

13.

Cortés, Javier, Hope S. Rugo, SM Tolaney, et al.. (2017). Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease. Annals of Oncology. 28. v80–v80. 1 indexed citations

14.

Tolaney, SM, et al.. (2017). Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. European Journal of Cancer. 72. S16–S16. 31 indexed citations

15.

Rugo, H. S., SM Tolaney, Maura N. Dickler, et al.. (2017). Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC). Cancer Research. 77(4_Supplement). OT2–1. 3 indexed citations

16.

Berry, DA, Bhupender Singh, C. Cirrincione, et al.. (2016). Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Cancer Research. 76(4_Supplement). S2–5. 51 indexed citations

17.

Beeram, Muralidhar, Thaddeus Beck, DA Richards, et al.. (2016). Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer. Cancer Research. 76(4_Supplement). P4–13. 6 indexed citations

18.

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

19.

Gucalp, Ayca, SM Tolaney, SJ Isakoff, et al.. (2011). TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). TPS122–TPS122. 4 indexed citations

20.

Tolaney, SM, Howard A. Burris, Elaina M. Gartner, et al.. (2011). P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.. Cancer Research. 71(24_Supplement). P1–17. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact